Tags

Type your tag names separated by a space and hit enter

Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Neurol Clin. 1990 Feb; 8(1):31-49.NC

Abstract

Recent advances in the understanding of the pharmacokinetics of levodopa and other anti-Parkinson agents have brought about the development of rational approaches to the management of levodopa-related fluctuations in motor performance that plague the majority of patients with advanced PD. The rapid systemic clearance of levodopa underlies the "short duration" response to the drug, which is progressively unmasked as PD progresses and central dopamine synthetic and storage capacity can no longer buffer fluctuations in plasma levodopa levels. Dyskinesias may be considered a secondary pharmacodynamic consequence of such pharmacokinetically induced oscillations in brain dopamine levels. Therapeutic approaches aimed at stabilizing brain dopaminergic activity include the use of slowly releasing galenic formulations of levodopa, synthetic dopamine agonists of long-lasting biologic activity, and drugs such as deprenyl that act as "dopamine extenders." It remains to be seen whether early use of such treatment approaches will reduce the prevalence of motor response fluctuations, which are one of the most disabling complications of long-term treatment of PD.

Authors+Show Affiliations

Cornell University Medical College.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

2181267

Citation

Cedarbaum, J M.. "Pharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's Disease." Neurologic Clinics, vol. 8, no. 1, 1990, pp. 31-49.
Cedarbaum JM. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease. Neurol Clin. 1990;8(1):31-49.
Cedarbaum, J. M. (1990). Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease. Neurologic Clinics, 8(1), 31-49.
Cedarbaum JM. Pharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's Disease. Neurol Clin. 1990;8(1):31-49. PubMed PMID: 2181267.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease. A1 - Cedarbaum,J M, PY - 1990/2/1/pubmed PY - 1990/2/1/medline PY - 1990/2/1/entrez SP - 31 EP - 49 JF - Neurologic clinics JO - Neurol Clin VL - 8 IS - 1 N2 - Recent advances in the understanding of the pharmacokinetics of levodopa and other anti-Parkinson agents have brought about the development of rational approaches to the management of levodopa-related fluctuations in motor performance that plague the majority of patients with advanced PD. The rapid systemic clearance of levodopa underlies the "short duration" response to the drug, which is progressively unmasked as PD progresses and central dopamine synthetic and storage capacity can no longer buffer fluctuations in plasma levodopa levels. Dyskinesias may be considered a secondary pharmacodynamic consequence of such pharmacokinetically induced oscillations in brain dopamine levels. Therapeutic approaches aimed at stabilizing brain dopaminergic activity include the use of slowly releasing galenic formulations of levodopa, synthetic dopamine agonists of long-lasting biologic activity, and drugs such as deprenyl that act as "dopamine extenders." It remains to be seen whether early use of such treatment approaches will reduce the prevalence of motor response fluctuations, which are one of the most disabling complications of long-term treatment of PD. SN - 0733-8619 UR - https://www.unboundmedicine.com/medline/citation/2181267/Pharmacokinetic_and_pharmacodynamic_considerations_in_management_of_motor_response_fluctuations_in_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.